SCHEMBL6537720

SCHEMBL6537720

CC(=O)c1c[nH]c2c([N+](=O)[O-])cccc2c1=O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNA2 P51530 1/20 0.78
CASP6 P55212 1/20 0.78
CTDSP1 Q9GZU7 1/20 0.78
GUSB P08236 3/20 0.49
BRPF1 P55201 1/20 0.49
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
CLEC4M Q9H2X3 1/20 0.45
PARP1 P09874 1/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 1/20 0.44
MAPK1 P28482 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
FBP1 P09467 3/20 0.43
DYRK1A Q13627 1/20 0.43
CLK1 P49759 1/20 0.43
GSK3B P49841 1/20 0.43
CDK5 Q00535 1/20 0.43
CDK5R1 Q15078 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3066032 0.90 DNA2 (0.66) DNA2CASP6CTDSP1GUSBBRPF1
SCHEMBL4334739 0.87 DNA2 (1.00) DNA2CASP6CTDSP1GUSBALDH1A1
SCHEMBL19220845 0.85 DNA2 (0.72) DNA2CASP6CTDSP1GUSBALDH1A1
SCHEMBL19220852 0.82 DNA2 (0.71) DNA2CASP6CTDSP1GUSBMAPT
SCHEMBL4739348 0.82 CLEC4M (0.71) DNA2CASP6CTDSP1GUSBALDH1A1
SCHEMBL1277854 0.81 DNA2 (0.83) DNA2CASP6CTDSP1ALDH1A1KDM4E
SCHEMBL6538267 0.80 DNA2 (0.63) DNA2CASP6CTDSP1GUSBALDH1A1
SCHEMBL19220847 0.79 DNA2 (0.62) DNA2CASP6CTDSP1GUSBALDH1A1
SCHEMBL6538006 0.77 DNA2 (0.68) DNA2CASP6CTDSP1GUSBALDH1A1
SCHEMBL19226218 0.77 DNA2 (0.60) DNA2CASP6CTDSP1GUSBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780815-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2023-10-10 US disclosed
US-20180134664-A1 DNA2 INHIBITORS FOR CANCER TREATMENT CITY OF HOPE 2018-05-17 US disclosed
US-9932310-B2 DNA2 inhibitors for cancer treatment CITY OF HOPE (US) 2018-04-03 US disclosed
US-20170226063-A1 DNA2 INHIBITORS FOR CANCER TREATMENT CITY OF HOPE 2017-08-10 US disclosed
EP-0876345-B1 HETEROCYCLIC COMPOUNDS AS H+-ATPASES FUJISAWA PHARMACEUTICAL CO (JP) 2004-08-18 EP disclosed
US-6008230-A TREATING BONE DISEASES CAUSED BY ABNORMAL BONE METABOLISM IN HUMAN BEING OR ANIMALS AS THE INHIBITORS OF BONE RESORPTION OR THE INHIBITORS OF BONE METASTASIS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-12-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134664-A1 DNA2 INHIBITORS FOR CANCER TREATMENT DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-20170226063-A1 DNA2 INHIBITORS FOR CANCER TREATMENT DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885
US-11780815-B2 DNA2 inhibitors for cancer treatment DNA2, TOP2A, TOP2B DNA2 1/4885CASP6 2412/4885CTDSP1 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.